Table 3.
Base-case cost-effectiveness results using deterministic values
| Ranibizumab | vPDT | Observation | Ranibizumab versus vPDT | Ranibizumab versus observation | |
|---|---|---|---|---|---|
| Cost (£) | 12,866 | 14,421 | 8,163 | −1,555 | +4,703 |
| QALYs | 12.99 | 12.60 | 12.45 | +0.39 | +0.54 |
| Life-years | 16.85 | 16.70 | 16.61 | +0.15 | +0.24 |
| NMB (£) | – | – | – | 9,289 | 6,013 |
| ICER (£/QALY) | – | – | – | Dominant | 8,778 |
The model followed a cohort of 1,000 patients over a lifetime time horizon. The healthcare provider perspective was adopted. Future costs and health outcomes were discounted at 3.5 % per annum
ICER incremental cost-effectiveness ratio, NMB net monetary benefit, QALY quality-adjusted life-year, vPDT verteporfin photodynamic therapy